<DOC>
	<DOCNO>NCT00133393</DOCNO>
	<brief_summary>The primary objective study identify safe , tolerable dose pentoxifylline child cerebral malaria establish acceptable pentoxifylline dosage regimen use multi center Phase II Phase III study .</brief_summary>
	<brief_title>Pentoxifylline Children With Malaria</brief_title>
	<detailed_description>This open , prospective , dose-escalating study , design elucidate pharmacokinetics , pharmacodynamics , safety , tolerability pentoxifylline child age great than/equal 9 month less than/equal 96 month cerebral malaria . The study design evaluate pentoxifylline adjunct therapy severe pediatric malaria evaluate toxicity associate adverse event , establish acceptable dose associate pharmacokinetic profile . The pharmacodynamic effect four different dose level ( 10 , 20 , 30 , 40 mg/kg/24 hour ) access follow biological , immunological , parasitological parameter : cerebral blood flow velocity , tumor necrosis factor concentration , rosetting , coma resolution time , parasite clearance time , fever clearance time . Due variability observe biological , immunological , parasitological parameter scrutiny , control group ten patient intercalate study ( 4 patient prior enrollment first pentoxifylline recipient , 2 patient in-between 3 dose escalation ) . As information relationship treatment duration biological , immunological , parasitological effect , treatment continue 72 hour , time peripheral parasitemia clear majority patient . The selection pentoxifylline dosage regimen large , multi center Phase II Phase III study make basis maximum tolerate dose ( base clinical laboratory observation ) minimize dose-related side-effects adverse event ( base pharmacokinetics ) permit maximum biological , immunological , and/or parasitological effect ( pharmacodynamics ) .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Children meeting follow criterion eligible inclusion study . Age great equal 9 month less equal 96 month . Informed consent grant parents/guardians ( Appendix I ) . Has cerebral malaria define follow : peripheral parasitemia asexual form P. falciparum ; inability localize painful stimulus 30 minute correct hypoglycemia ( blood glucose less 2.2 mmol/l ) patient present hypoglycemia 30 minute cessation convulsive activity patient convulse admission ; neck stiffness ; clinical evidence pneumonia ( rale , decrease breath sound , bronchial breathing ) . Children follow enrol study : Hypotension : mean blood pressure le 60 mmHg ( mean blood pressure = diastolic blood pressure ( mmHg ) + 1/3 ( systolic blood pressure diastolic blood pressure ) ) . Thrombocytopenia : platelet count le 50 x 10 ( ninth power ) /l . Spontaneous bleed noted mouth , throat , naris , rectum , venipuncture site follow adequate pressure . Hematocrit &lt; 20 % OR hematocrit 2025 % parasitemia great 10 % .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>96 Months</maximum_age>
	<verification_date>October 2005</verification_date>
</DOC>